ArticleJournal of experimental & clinical cancer research : CR2011
In vivo molecular targeting effects of anti-Sp17- ICG-Der-02 on hepatocellular carcinoma evaluated by an optical imaging system.
Article in Journal of experimental & clinical cancer research : CR, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative effectiveness of radiofrequency ablation with or without transarterial chemoembolization for hepatocellular carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Review
- A narrative review of near-infrared fluorescence imaging in hepatectomy for hepatocellular carcinoma.Annals of translational medicine · 2021Review
- Phosphodiesterase type 5 inhibitor Tadalafil increases Rituximab treatment efficacy in a mouse brain lymphoma model.Journal of neuro-oncology · 2015Article
- Anti-Sp17 monoclonal antibody-doxorubicin conjugates as molecularly targeted chemotherapy for ovarian carcinoma.Targeted oncology · 2014Article
- Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells.Medical oncology (Northwood, London, England) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs the expression of human sperm protein 17 (Sp17) in normal tissue is limited and the function is obscure, its aberrant expression in malignant tumors makes it to be a candidated molecular marker for tumor imaging diagnosis and targeting therapy of the diseases.The aim of this research is to evaluate the targeting effects of anti-sperm protein 17 monoclonal antibody (anti-Sp17) on cancer in vivo and investigate its usefulness as a reagent for molecular imaging diagnosis.
methodsImmunohistochemistry was used to identify the expression of Sp17 in a hepatocellular carcinoma cell line and tumor xenograft specimens. A near infrared fluorescence dye, ICG-Der-02, was covalently linked to anti-Sp17 for in vivo imaging. The immuno-activity of the anti-Sp17-ICG-Der-02 complex was tested in vitro by ELISA; it was then injected into tumor-bearing nude mice through the caudal vein to evaluate its tumor targeting effect by near infrared imaging system.
resultsOverexpression of Sp17 on the surface of the hepatocellular carcinoma cell line SMMC-7721 was demonstrated. Anti-Sp17-ICG-Der-02 with immuno-activity was successfully synthesized. The immuno-activity and photo stability of anti-Sp17- ICG-Der-02 showed good targeting capability for Sp17 expressing tumor models (SMMC-7721) in vivo, and its accumulation in the tumor lasted for at least 7 days.
conclusionsAnti-Sp17 antibody targeted and accumulated in Sp17 positive tumors in vivo, which demonstrated its capability of serving as a diagnostic reagent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.